A Phase 3 interventional study of Gabapentin and Placebo in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 23 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one has the largest planned enrollment, is one of 5 that started in 2004, is one of 9 in phase 3, and was the 3rd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,105 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 283 across the 14 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 9 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Gabapentin
Drug: Placebo
Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
Adverse Events
Time frame: Day 45
Pulse and Blood Pressure
Time frame: Day 45
Subjective proportion of nights having difficulty sleeping
Time frame: Day 45
Subjective Sleep Latency
Time frame: Day 45
Subjective Wake After Sleep Onset
Time frame: Day 45
Subjective Number of Awakenings
Time frame: Day 45
Subjective Total Sleep Time
Time frame: Day 45
Subjective Assessment of Sleep Quality
Time frame: Day 45
Subjective Assessment of Ease of Awakening
Time frame: Day 45
Subject Global Evaluation
Time frame: Day 45
Pittsburg Sleep Quality Index
Time frame: Day 45
The record gives a start of Dec 2004 and a completion of May 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Sleep Initiation and Maintenance Disorders →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →